ASI’s Riverview facility to manufacture Ponatinib API
The FDA approved the drug on December 14, 2012 for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The settlement also resolves similar open civil investigations against Walgreens Jupiter Distribution Center and six Walgreens retail pharmacies (together known as "Registrants") in Florida, Colorado, Michigan and Eastern